<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00284856</url>
  </required_header>
  <id_info>
    <org_study_id>0476-332</org_study_id>
    <secondary_id>2005_108</secondary_id>
    <nct_id>NCT00284856</nct_id>
  </id_info>
  <brief_title>Montelukast Asthmatic Smoker Study (0476-332)(COMPLETED)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Parallel-Group 6-Month Study to Evaluate the Efficacy and Safety of Oral Montelukast Sodium, Fluticasone Propionate and Placebo in Patients With Chronic Asthma Who Smoke Cigarettes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter study to evaluate the efficacy and safety of MK0476 versus placebo in
      participants with chronic asthma who actively smoke cigarettes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Asthma-control Days Over the 6-month Treatment Period</measure>
    <time_frame>6 months</time_frame>
    <description>An asthma-control day, computed from daily diaries, was any day with no unscheduled visit for asthma care, no use of &gt; than 2 puffs of β-agonist, no use of other asthma rescue medication, and no nocturnal awakening. The percentage of asthma-control days was the number of days with asthma-control divided by the total number of days with non-missing values for this endpoint. The patient diary had questions concerning daytime and nighttime symptoms, morning (AM) and evening (PM) peak expiratory flow rate (PEFR), β-agonist use, asthma attacks and smoking activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Daytime Symptom Score Over a 6-month Treatment Period</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>4 daytime symptoms were evaluated daily on a 7-point scale from 0 (best)- 6 (worst). The on-treatment daytime symptom score was computed by averaging over Period II the mean of the 4 daily symptom scores recorded daily in the diary while the baseline daytime symptom score was obtained by averaging the mean of the 4 daily symptom scores across the daily diary entries of the Baseline period (Period I). The change from baseline in mean daytime symptom score is computed as the difference between the mean on-treatment daytime symptom score &amp; the mean baseline daytime symptom score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Morning (AM) PEFR (Peak Expiratory Flow Rate) Over a 6-month Treatment Period</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>PEFR measurements were performed daily, in the morning before using any medication. The on-treatment AM PEFR was computed by averaging over Period II (treatment period) the AM PEFR recorded daily in the diary, while the baseline AM PEFR was obtained by averaging the AM PEFR across the daily diary entries of the Baseline Period or Period I (placebo run-in period). The change from baseline in average AM PEFR is computed as the difference between mean on-treatment AM PEFR and mean baseline AM PEFR.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1640</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1: Montelukast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2: Fluticasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm 3: Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>montelukast sodium</intervention_name>
    <description>montelukast 10 mg tablet once daily, 6 month treatment period</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>fluticasone propionate 250 mcg Placebo (Pbo) twice daily, 6 month treatment period</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: fluticasone</intervention_name>
    <description>fluticasone propionate 250 mcg twice daily, 6 month treatment period</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>montelukast 10 mg Pbo tablet once daily, 6 month treatment period</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with chronic asthma who actively smoke at least 0.5 to no more than 2
             packs of cigarettes a day

        Exclusion Criteria:

          -  Participant cannot have a diagnosis of Chronic Obstructive Pulmonary Disease (COPD) or
             emphysema.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Ecuador</country>
    <country>Egypt</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Lebanon</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovenia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Arab Emirates</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <results_reference>
    <citation>Price D, Popov TA, Bjermer L, Lu S, Petrovic R, Vandormael K, Mehta A, Strus JD, Polos PG, Philip G. Effect of montelukast for treatment of asthma in cigarette smokers. J Allergy Clin Immunol. 2013 Mar;131(3):763-71. doi: 10.1016/j.jaci.2012.12.673. Epub 2013 Feb 4.</citation>
    <PMID>23380218</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2006</study_first_submitted>
  <study_first_submitted_qc>January 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2006</study_first_posted>
  <results_first_submitted>April 6, 2011</results_first_submitted>
  <results_first_submitted_qc>April 6, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 3, 2011</results_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of the 1640 participants enrolled in the study, 621 participants were excluded during screening and not randomized. The remaining 1019 participants were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Montelukast</title>
          <description>Montelukast 10 mg tablet once daily at bedtime and Fluticasone propionate matching placebo 250 mcg twice daily for 6 months</description>
        </group>
        <group group_id="P2">
          <title>Fluticasone</title>
          <description>Fluticasone propionate 250 mcg twice daily and Montelukast matching placebo 10 mg tablet once daily at bedtime for 6 months</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Montelukast matching placebo 10 mg tablet once daily at bedtime and Fluticasone propionate matching placebo 250 mcg twice daily for 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="347"/>
                <participants group_id="P2" count="336"/>
                <participants group_id="P3" count="336"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="296"/>
                <participants group_id="P2" count="286"/>
                <participants group_id="P3" count="276"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="60"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Montelukast</title>
          <description>Montelukast 10 mg tablet once daily at bedtime and Fluticasone propionate matching placebo 250 mcg twice daily for 6 months</description>
        </group>
        <group group_id="B2">
          <title>Fluticasone</title>
          <description>Fluticasone propionate 250 mcg twice daily and Montelukast matching placebo 10 mg tablet once daily at bedtime for 6 months</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Montelukast matching placebo 10 mg tablet once daily at bedtime and Fluticasone propionate matching placebo 250 mcg twice daily for 6 months</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="347"/>
            <count group_id="B2" value="336"/>
            <count group_id="B3" value="336"/>
            <count group_id="B4" value="1019"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.7" spread="10.4"/>
                    <measurement group_id="B2" value="38.4" spread="10.7"/>
                    <measurement group_id="B3" value="37.9" spread="9.9"/>
                    <measurement group_id="B4" value="38.0" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="163"/>
                    <measurement group_id="B2" value="147"/>
                    <measurement group_id="B3" value="166"/>
                    <measurement group_id="B4" value="476"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="184"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="170"/>
                    <measurement group_id="B4" value="543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Asthma-control Days Over the 6-month Treatment Period</title>
        <description>An asthma-control day, computed from daily diaries, was any day with no unscheduled visit for asthma care, no use of &gt; than 2 puffs of β-agonist, no use of other asthma rescue medication, and no nocturnal awakening. The percentage of asthma-control days was the number of days with asthma-control divided by the total number of days with non-missing values for this endpoint. The patient diary had questions concerning daytime and nighttime symptoms, morning (AM) and evening (PM) peak expiratory flow rate (PEFR), β-agonist use, asthma attacks and smoking activity.</description>
        <time_frame>6 months</time_frame>
        <population>Efficacy analysis was based on the full analysis set (FAS) population which included all participants who had at least 7 days of on-treatment data for the specific endpoint. Thirty three patients were excluded from the FAS (13 on montelukast, 7 on fluticasone and 13 on placebo). One participant in the placebo group did not take study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast</title>
            <description>Montelukast 10 mg tablet once daily at bedtime and Fluticasone propionate matching placebo 250 mcg twice daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone</title>
            <description>Fluticasone propionate 250 mcg twice daily and Montelukast matching placebo 10 mg tablet once daily at bedtime for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Montelukast matching placebo 10 mg tablet once daily at bedtime and Fluticasone propionate matching placebo 250 mcg twice daily for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Asthma-control Days Over the 6-month Treatment Period</title>
          <description>An asthma-control day, computed from daily diaries, was any day with no unscheduled visit for asthma care, no use of &gt; than 2 puffs of β-agonist, no use of other asthma rescue medication, and no nocturnal awakening. The percentage of asthma-control days was the number of days with asthma-control divided by the total number of days with non-missing values for this endpoint. The patient diary had questions concerning daytime and nighttime symptoms, morning (AM) and evening (PM) peak expiratory flow rate (PEFR), β-agonist use, asthma attacks and smoking activity.</description>
          <population>Efficacy analysis was based on the full analysis set (FAS) population which included all participants who had at least 7 days of on-treatment data for the specific endpoint. Thirty three patients were excluded from the FAS (13 on montelukast, 7 on fluticasone and 13 on placebo). One participant in the placebo group did not take study medication.</population>
          <units>Percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="329"/>
                <count group_id="O3" value="323"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.70" spread="38.19" lower_limit="40.62" upper_limit="49.33"/>
                    <measurement group_id="O2" value="53.30" spread="39.06" lower_limit="44.86" upper_limit="53.53"/>
                    <measurement group_id="O3" value="43.84" spread="38.08" lower_limit="34.65" upper_limit="43.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>5.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>11.56</ci_upper_limit>
            <estimate_desc>Estimated Value is difference in least squares mean (montelukast - placebo)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>10.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.50</ci_lower_limit>
            <ci_upper_limit>15.78</ci_upper_limit>
            <estimate_desc>Estimated value is difference in least squares mean (fluticasone - placebo)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-4.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.83</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
            <estimate_desc>Estimated value is difference in least squares mean (montelukast - fluticasone)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Daytime Symptom Score Over a 6-month Treatment Period</title>
        <description>4 daytime symptoms were evaluated daily on a 7-point scale from 0 (best)- 6 (worst). The on-treatment daytime symptom score was computed by averaging over Period II the mean of the 4 daily symptom scores recorded daily in the diary while the baseline daytime symptom score was obtained by averaging the mean of the 4 daily symptom scores across the daily diary entries of the Baseline period (Period I). The change from baseline in mean daytime symptom score is computed as the difference between the mean on-treatment daytime symptom score &amp; the mean baseline daytime symptom score.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Efficacy analysis was based on the full analysis set (FAS) population which included all participants who received at least one dose of the randomized double-blind study medication and who had at least 7 days of on-treatment data for the specific endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast</title>
            <description>Montelukast 10 mg tablet once daily at bedtime and Fluticasone propionate matching placebo 250 mcg twice daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone</title>
            <description>Fluticasone propionate 250 mcg twice daily and Montelukast matching placebo 10 mg tablet once daily at bedtime for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Montelukast matching placebo 10 mg tablet once daily at bedtime and Fluticasone propionate matching placebo 250 mcg twice daily for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Daytime Symptom Score Over a 6-month Treatment Period</title>
          <description>4 daytime symptoms were evaluated daily on a 7-point scale from 0 (best)- 6 (worst). The on-treatment daytime symptom score was computed by averaging over Period II the mean of the 4 daily symptom scores recorded daily in the diary while the baseline daytime symptom score was obtained by averaging the mean of the 4 daily symptom scores across the daily diary entries of the Baseline period (Period I). The change from baseline in mean daytime symptom score is computed as the difference between the mean on-treatment daytime symptom score &amp; the mean baseline daytime symptom score.</description>
          <population>Efficacy analysis was based on the full analysis set (FAS) population which included all participants who received at least one dose of the randomized double-blind study medication and who had at least 7 days of on-treatment data for the specific endpoint.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="335"/>
                <count group_id="O2" value="329"/>
                <count group_id="O3" value="322"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" spread="1.03" lower_limit="-0.53" upper_limit="-0.37"/>
                    <measurement group_id="O2" value="1.78" spread="0.97" lower_limit="-0.58" upper_limit="-0.42"/>
                    <measurement group_id="O3" value="1.90" spread="0.94" lower_limit="-0.38" upper_limit="-0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average Change from Baseline During Period II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.70"/>
                    <measurement group_id="O2" value="-0.44" spread="0.68"/>
                    <measurement group_id="O3" value="-0.27" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.25</ci_lower_limit>
            <ci_upper_limit>-0.05</ci_upper_limit>
            <estimate_desc>Estimated value is difference in least squares mean (montelukast - placebo)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>-0.10</ci_upper_limit>
            <estimate_desc>Estimated value is difference in least squares mean (fluticasone - placebo)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.15</ci_upper_limit>
            <estimate_desc>Estimated value is difference in least squares mean (montelukast - fluticasone)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Morning (AM) PEFR (Peak Expiratory Flow Rate) Over a 6-month Treatment Period</title>
        <description>PEFR measurements were performed daily, in the morning before using any medication. The on-treatment AM PEFR was computed by averaging over Period II (treatment period) the AM PEFR recorded daily in the diary, while the baseline AM PEFR was obtained by averaging the AM PEFR across the daily diary entries of the Baseline Period or Period I (placebo run-in period). The change from baseline in average AM PEFR is computed as the difference between mean on-treatment AM PEFR and mean baseline AM PEFR.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Efficacy analysis was based on the full analysis set (FAS) population which included all participants who received at least one dose of the randomized double-blind study medication and who had at least 7 days of on-treatment data for the specific endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast</title>
            <description>Montelukast 10 mg tablet once daily at bedtime and Fluticasone propionate matching placebo 250 mcg twice daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone</title>
            <description>Fluticasone propionate 250 mcg twice daily and Montelukast matching placebo 10 mg tablet once daily at bedtime for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Montelukast matching placebo 10 mg tablet once daily at bedtime and Fluticasone propionate matching placebo 250 mcg twice daily for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Morning (AM) PEFR (Peak Expiratory Flow Rate) Over a 6-month Treatment Period</title>
          <description>PEFR measurements were performed daily, in the morning before using any medication. The on-treatment AM PEFR was computed by averaging over Period II (treatment period) the AM PEFR recorded daily in the diary, while the baseline AM PEFR was obtained by averaging the AM PEFR across the daily diary entries of the Baseline Period or Period I (placebo run-in period). The change from baseline in average AM PEFR is computed as the difference between mean on-treatment AM PEFR and mean baseline AM PEFR.</description>
          <population>Efficacy analysis was based on the full analysis set (FAS) population which included all participants who received at least one dose of the randomized double-blind study medication and who had at least 7 days of on-treatment data for the specific endpoint.</population>
          <units>Liters/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="329"/>
                <count group_id="O3" value="324"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="363.75" spread="112.40"/>
                    <measurement group_id="O2" value="354.28" spread="101.64"/>
                    <measurement group_id="O3" value="347.98" spread="99.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average Change from Baseline During Period II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.84" spread="40.22"/>
                    <measurement group_id="O2" value="19.31" spread="44.85"/>
                    <measurement group_id="O3" value="8.27" spread="40.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>5.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.27</ci_lower_limit>
            <ci_upper_limit>11.45</ci_upper_limit>
            <estimate_desc>Estimated value is difference in least squares mean (montelukast - placebo)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>11.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.85</ci_lower_limit>
            <ci_upper_limit>17.58</ci_upper_limit>
            <estimate_desc>Estimated value is difference in least squares mean (fluticasone - placebo)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-6.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-12.46</ci_lower_limit>
            <ci_upper_limit>0.20</ci_upper_limit>
            <estimate_desc>Estimated value is difference in least squares mean (montelukast - fluticasone)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The population for safety analyses was the All Patients as Treated (APaT) set.
The set included all randomized participants who took at least one dose of the
double-blind study medication. One participant in the placebo group was randomized but did not take treatment. Therefore, participant was not included in the safety analyses.</desc>
      <group_list>
        <group group_id="E1">
          <title>Montelukast</title>
          <description>Montelukast 10 mg tablet once daily at bedtime and Fluticasone propionate matching placebo 250 mcg twice daily for 6 months</description>
        </group>
        <group group_id="E2">
          <title>Fluticasone</title>
          <description>Fluticasone propionate 250 mcg twice daily and Montelukast matching placebo 10 mg tablet once daily at bedtime for 6 months</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Montelukast matching placebo 10 mg tablet once daily at bedtime and Fluticasone propionate matching placebo 250 mcg twice daily for 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Dermoid cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="335"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="335"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="335"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="335"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="335"/>
              </event>
              <event>
                <sub_title>Salpingo-oophoritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="335"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="335"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="335"/>
              </event>
              <event>
                <sub_title>Brain herniation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="335"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="335"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="335"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="335"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="335"/>
              </event>
              <event>
                <sub_title>Facial palsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="335"/>
              </event>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="335"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="30" subjects_affected="23" subjects_at_risk="347"/>
                <counts group_id="E2" events="34" subjects_affected="27" subjects_at_risk="336"/>
                <counts group_id="E3" events="26" subjects_affected="22" subjects_at_risk="335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="71" subjects_affected="45" subjects_at_risk="347"/>
                <counts group_id="E2" events="50" subjects_affected="34" subjects_at_risk="336"/>
                <counts group_id="E3" events="95" subjects_affected="57" subjects_at_risk="335"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The SPONSOR must have the opportunity to review all proposed abstracts,
manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as
confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

